| 前收市價 | 75.65 |
| 開市 | 77.05 |
| 買盤 | 74.55 |
| 賣出價 | 80.85 |
| 拍板 | 750.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 76.15 - 77.24 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 48 |
Investor's Business DailyDow Jones Futures: Market Rally Narrows; Dow Giants Lead 7 Stocks Near Buy Points
The market rally had a mixed week as breadth narrowed. Microsoft and Merck led stocks near buy points. Here's what to do.
BenzingaEli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion. This expansion will enhance Lilly’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Related: Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires M
ReutersLilly invests further $5.3 billion in new Indiana site as obesity drug demand soars
(Reuters) -Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs. The new investment, which brings the total to $9 billion, will help boost production of the active pharmaceutical ingredients (API) for Lilly's powerful weight-loss drug Zepbound and diabetes treatment Mounjaro, the company said. “Today’s announcement tops the largest manufacturing investment in our company’s history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history,” said Lilly CEO David Ricks.
